Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Dietrich on Navigating the NSCLC Treatment Landscape

August 25th 2021

Martin Dietrich, MD, PhD, shares how he navigates the non–small cell lung cancer (NSCLC) treatment landscape.

Immunotherapy for NSCLC: Clinical Pearls

August 25th 2021

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

Blood-Based Biomarkers in NSCLC

August 25th 2021

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Perioperative Approaches to NSCLC

August 25th 2021

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Dr. Pecot on Addressing Mechanisms of Resistance With New Targeted Therapies in NSCLC

August 24th 2021

Chad V. Pecot, MD, discusses addressing mechanisms of resistance with new targeted therapies in non–small cell lung cancer.

Dr. Stevenson on Ongoing Research Efforts in ES-SCLC

August 23rd 2021

James Stevenson, MD, discusses ongoing research efforts that are generating excitement in extensive-stage small cell lung cancer.

CT-Based Image Guidance Identifies COVID-19 in Radiotherapy Treated–Lung Cancer

August 20th 2021

Computed tomography-based image guidance during radiation therapy could be a method of identifying patients who require a complete workup for COVID-19.

Dr. Spicer on Outcomes from the CheckMate-816 Trial in NSCLC

August 20th 2021

Jonathan Spicer, MD, PhD, discusses the efficacy observed with neoadjuvant nivolumab plus platinum-doublet chemotherapy in patients with resectable non–small cell lung cancer.

Toripalimab Plus Chemo Meets PFS End Point in Frontline Advanced NSCLC

August 19th 2021

The addition of toripalimab to chemotherapy resulted in a significant improvement in progression-free survival compared with chemotherapy alone when given as first-line treatment in patients with non–small cell lung cancer, meeting the primary end point of the phase 3 CHOICE-01 trial.

Nivolumab Followed by TIL Therapy Shows Early Safety, Clinical Activity in Metastatic NSCLC

August 19th 2021

Nivolumab followed by treatment with tumor-infiltrating lymphocytes was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer.

ROS1-Rearranged NSCLC: Updates FromASCO

August 19th 2021

An overview of TKIs in ROS1-rearranged non–small cell lung cancer (NSCLC) and updated trial results that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting.

EGFR Mutation Heterogeneity

August 19th 2021

Recommendations for EGFR testing in patients with non–small cell lung cancer based on the wide heterogeneity of these mutations.

New Therapies for NSCLC With EGFR Exon 20 Insertions

August 19th 2021

Mark A. Socinski, MD, highlights the targeted agents available to treat non–small cell lung cancer with EGFR mutations.

Emerging Treatments in SCLC: Triplets + Limited-Stage Disease

August 19th 2021

Anne Chiang, MD, PhD, reviews the study design of 2 clinical trials, adding a third agent to the standard-of-care regimen of chemotherapy plus I/O; Stephen Liu, MD, discusses clinical trials in limited-stage disease.

Emerging Treatments in SCLC: Targeting DNA Damage

August 19th 2021

Thoracic oncology expert Vivek Subbiah, MD, provides an overview of recent clinical trials studying agents targeting DNA damage for the treatment of small cell lung cancer.

Preferred Treatment for ALK-Rearranged NSCLC

August 19th 2021

Experts have a discussion about their preferred treatment approach for newly diagnosed ALK-rearranged non–small cell lung cancer (NSCLC).

Mobocertinib’s Safety Profile

August 19th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors.

Biomarkers for Immunotherapy in Resectable NSCLC

August 18th 2021

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

PD-1/Chemo Combos Raise the Stakes in SCLC, as Focus Shifts to Leveraging Molecular Testing

August 18th 2021

Jonathan W. Goldman, MD, discusses the significance of the phase 3 CASPIAN and IMpower133 trials in small cell lung cancer and efforts made to optimize molecular testing.

Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC

August 18th 2021

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.